La maladie de Parkinson au Canada (serveur d'exploration) - Merge (PascalFrancis)

Index « FA11s1.i » - entrée « CALNE (D. B.) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
CALLIER (Sophie) < CALNE (D. B.) < CALNE (D.)  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 65.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000000 (1999) J. K. C. Tsui ; D. B. Calne ; YUE WANG ; M. Schulzer ; S. A. MarionOccupational risk factors in Parkinson's disease
000001 (1999) A. Samii ; K. Markopoulou ; Z. K. Wszolek ; V. Sossi ; T. Dobko ; E. Mak ; D. B. Calne ; A. J. StoesslPET studies of parkinsonism associated with mutation in the α-synuclein gene
000003 (2000) P. K. Pal ; D. B. Calne ; S. Calne ; J. K. C. TsuiBotulinum toxin A as treatment for drooling saliva in PD
000006 (2000) B. J. Snow ; F. J. G. Vingerhoets ; J. W. Langston ; J. W. Tetrud ; V. Sossi ; D. B. CalnePattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism
000012 (2000) R. De La Fuente-Fernandez ; P. K. Pal ; F. J. G. Vingerhoets ; A. Kishore ; M. Schulzer ; E. K. Mak ; T. J. Ruth ; B. J. Snow ; D. B. Calne ; A. J. StoesslEvidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations
000017 (2000) C. S. Lee ; A. Samii ; V. Sossi ; T. J. Ruth ; M. Schulzer ; J. E. Holden ; J. Wudel ; P. K. Pal ; R. De La Fuente-Fernandez ; D. B. Calne ; A. J. StoesslIn vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease
000050 (2000) P. K. Pal ; A. Samii ; A. Kishore ; M. Schulzer ; E. Mak ; S. Yardley ; I. M. Turnbull ; D. B. CalneLong term outcome of unilateral pallidotomy : Follow up of 15 patients for 3 years
000052 (2000) R. De La Fuente-Fernandez ; A. Kishore ; D. B. Calne ; T. J. Ruth ; A. J. StoesslNigrostriatal dopamine system and motor lateralization
000282 (2003) G. V. Mcdonnell ; J. Cabrera-Gomez ; D. B. Calne ; D. K. B. Li ; J. OgerClinical presentation of primary progressive multiple sclerosis 10 years after the incidental finding of typical magnetic resonance imaging brain lesions: The subclinical stage of primary progressive multiple sclerosis may last 10 years
000323 (2004) Z. K. Wszolek ; R. F. Pfeiffer ; Y. Tsuboi ; R. J. Uitti ; R. D. Mccomb ; A. J. Stoessl ; A. J. Strongosky ; A. Zimprich ; B. Müller-Myhsok ; M. J. Farrer ; T. Gasser ; D. B. Calne ; D. W. DicksonAutosomal dominant parkinsonism associated with variable synuclein and tau pathology
000C19 (1995) H. Shinotoh ; D. B. CalneThe use of PET in Parkinson's disease
000C28 (1984) T. A. Larsen ; R. Newman ; P. Lewitt ; D. B. CalneSeverity of Parkinsońs disease and the dosage of bromocriptine
000C51 (1986) D. B. Calne ; E. Mcgeer ; A. Eisen ; P. SpencerAlzheimer's disease, Parkinson's disease, and motoneurone disease: abiotropic interaction between ageing and environment?
000C54 (1986) H. Teravainen ; L. Forgach ; M. Hietanen ; M. Schulzer ; B. Schoenberg ; D. B. CalneThe age of onset of Parkinson's disease: etiological implications
000C60 (1986) C. B. Bozek ; O. Suchowersky ; S. Purves ; S. Calne ; D. B. CalneSinemet in Parkinson's disease: efficacy with and without food
000C73 (1986) E. Lau ; K. Waterman ; R. Glover ; M. Schulzer ; D. B. CalneEffect of antacid on levodopa therapy
000C79 (1987) S. Calne ; B. Schoenberg ; W. Martin ; R. J. Uitti ; P. Spencer ; D. B. CalneFamilial Parkinson's disease: possible role of environmental factors
000D00 (1988) T. A. Hurwitz ; D. B. Calne ; K. WatermanTreatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy
000D08 (1988) D. B. Calne ; A. J. LeesLate progression of post encephalitic Parkinson's syndrome
000D14 (1989) E. C. Wolters ; T. A. Hurwitz ; R. F. Peppard ; D. B. CalneClozapine: an antipsychotic agent in Parkinson's disease?
000D19 (1989) J. K. C. Tsui ; E. C. Wolters ; R. F. Peppard ; D. B. CalneA double-blind, placebo-controlled, dose-ranging study to investigate the safety and efficacy of CY 208-243 in patients with Parkinson's disease

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Merge
HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Merge/FA11s1.i -k "CALNE (D. B.)" 
HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Merge/FA11s1.i  \
                -Sk "CALNE (D. B.)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PascalFrancis/Merge/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Merge
   |type=    indexItem
   |index=    FA11s1.i
   |clé=    CALNE (D. B.)
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022